용해도가 향상된 마이크로캡슐 함유 레바미피드 서방성 정제의 개발

초록

This study aims to develop a sustained-release tablet with rebamipide microcapsule that enhances solubility and dissolution rate compared to commercial product. Crystalline rebamipide was transformed into amorphous rebamipide microcapsule via solvent evaporation, and its physicochemical properties were compared with the crystalline form. To determine the optimal formulation, hypromellose 2208 4000 cps was used at different ratios and compared. The selected tablet composition, using direct compression, included a rebamipide microcapsule, lactose monohydrate, microcrystalline cellulose, hypromellose 2208 4000 cps, Kollidon VA64, croscarmellose sodium, and magnesium stearate in the weight ratio of 525/100/100/75/50/20/10 (w/w/w/w/w/w/w). Dissolution tests showed the prepared tablet had improved rates in water and similar behavior in a pH 6.8 buffer compared to the commercial tablet. This formulation is considered to have potential for use in the development of sustained-release rebamipide tablet with superior manufacturing efficiency and enhanced bioavailability.

키워드